Medical Editor: John P. Cunha, DO, FACOEP
Norpace (disopyramide phosphate) is an anti-arrhythmic drug used to treat seriously irregular heartbeat patterns. Norpace is available in generic form. Common side effects of Norpace include dry mouth, constipation, nausea, abdominal pain, gas, bloating, blurred vision, dry nose/eyes/throat, dizziness, tiredness, muscle aches or pains, rash, itching, and urination problems (such as difficulty urinating or unusual frequent urge to urinate).
The usual adult dosage of Norpace or Norpace CR is 400 to 800 mg per day given in divided doses. Norpace may interact with other anti-arrhythmics, beta-blockers, erythromycin, clarithromycin, phenytoin, phenobarbital, cisapride, rifampin, or warfarin. Tell your doctor all medications you use. During pregnancy, Norpace should be used only when prescribed. Rarely, this drug may cause early labor during pregnancy. Discuss the risks and benefits with your doctor. This medication passes into breast milk, and the effect on a nursing infant is unknown. Consult your doctor before breastfeeding.
Our Norpace (disopyramide phosphate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
If you experience any of the following serious side effects, stop taking disopyramide and seek emergency medical attention:
- an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
- a new or a worsening irregular heartbeat pattern;
- chest pain, chest discomfort, shortness of breath, or swelling of your legs or feet; or
- severe dizziness.
Other, less serious side effects may be more likely to occur. Talk to your doctor if you experience
- mild dizziness or tiredness,
- blurred vision,
- dry mouth,
- rash, itching,
- muscle aches or pains, or
- difficulty urinating.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Norpace (Disopyramide Phosphate)
The adverse reactions which were reported in Nor-pace clinical trials encompass observations in 1,500 patients, including 90 patients studied for at least 4 years. The most serious adverse reactions are hypo-tension and congestive heart failure. The most common adverse reactions, which are dose dependent, are associated with the anticholinergic properties of the drug. These may be transitory, but may be persistent or can be severe. Urinary retention is the most serious anticholinergic effect.
The following reactions were reported in 10% to 40% of patients:
Anticholinergic: dry mouth (32%), urinary hesitancy (14%), constipation (11%)
The following reactions were reported in 3% to 9% of patients:
Genitourinary: urinary retention, urinary frequency and urgency
Gastrointestinal: nausea, pain/bloating/gas
General: dizziness, general fatigue/muscle weakness, headache, malaise, aches/pains
The following reactions were reported in 1% to 3% of patients:
Cardiovascular: hypotension with or without congestive heart failure, increased congestive heart failure (see WARNINGS), cardiac conduction disturbances (see WARNINGS), edema/weight gain, shortness of breath, syncope, chest pain
Dermatologic: generalized rash/dermatoses, itching
Central nervous system: nervousness
Other: hypokalemia, elevated cholesterol/triglycerides
The following reactions were reported in less than 1%:
Depression, insomnia, dysuria, numbness/tingling, elevated liver enzymes, AV block, elevated BUN, elevated creatinine, decreased hemoglobin/hematocrit Hypoglycemia has been reported in association with Norpace administration (see WARNINGS).
Infrequent occurrences of reversible cholestatic jaundice, fever, and respiratory difficulty have been reported in association with disopyramide therapy, as have rare instances of thrombocytopenia, reversible agranulocytosis, and gynecomastia. Some cases of LE (lupus erythematosus) symptoms have been reported; most cases occurred in patients who had been switched to disopyramide from procaina-mide following the development of LE symptoms. Rarely, acute psychosis has been reported following Norpace (disopyramide phosphate) therapy, with prompt return to normal mental status when therapy was stopped. The physician should be aware of these possible reactions and should discontinue Norpace (disopyramide phosphate) or Norpace (disopyramide phosphate) CR therapy promptly if they occur.
Read the entire FDA prescribing information for Norpace (Disopyramide Phosphate)
© Norpace Patient Information is supplied by Cerner Multum, Inc. and Norpace Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.